The Promise of CAR T-Cell Therapy for the Treatment of Cancer Stem Cells: A Short Review

被引：7
作者：
Poondla, Naresh [1 ]
Sheykhhasan, Mohsen [2 ,3 ]
Akbari, Mohammad [4 ]
Samadi, Pouria [2 ]
Kalhor, Naser [3 ]
Manoochehri, Hamed [2 ]
机构：
[1] Univ Richmond, Med Ctr, 355 Bard Ave, Staten Isl, NY 10310 USA
[2] Hamadan Univ Med Sci, Res Ctr Mol Med, Hamadan, Iran
[3] Acad Ctr Educ Culture & Res ACECR, Dept Mesenchymal Stem Cells, Qom Branch, Tehran, Iran
[4] Islamic Azad Univ, Tonekabon Branch, Dept Med Sch, Fac Med Sci, Mazandaran, Iran
来源：
CURRENT STEM CELL RESEARCH & THERAPY | 2022年 / 17卷 / 05期
关键词：
CAR T-cell; cancer stem cells; malignancy; immunotherapy; antigens; cell surface markers; IMMUNOTHERAPY; CHALLENGES; MARKER; TUMORS;
D O I：
10.2174/1574888X17666220217101817
中图分类号：
Q813 [细胞工程];
学科分类号：
摘要：
Chimeric antigen receptor (CAR) T-cell therapy is a type of sophisticated tailored immunotherapy used to treat a variety of tumors. Immunotherapy works by utilizing the body's own immune system to discover and destroy malignant cells. In CAR-T therapy, a patient's own immune cells are genetically engineered to recognize and attack cancer. Treatments employing CAR T-cells are currently showing promising therapeutic results in patients with hematologic malignancies, and their safety and feasibility in solid tumors have been verified. In this review, we will discuss in detail the likelihood that CAR T-cells inhibit cancer stem cells (CSCs) by selectively targeting their cell surface markers will ultimately improve the therapeutic response for patients with various forms of cancer. This review addresses the major components of cancer stem cell (CSC)-targeted CAR T-cells against malignancies, from bench to bedside.
引用
收藏
页码：400 / 406
页数：7
相关论文
共 36 条
  • [1] scFv Antibody: Principles and Clinical Application
    Ahmad, Zuhaida Asra
    Yeap, Swee Keong
    Ali, Abdul Manaf
    Ho, Wan Yong
    Alitheen, Noorjahan Banu Mohamed
    Hamid, Muhajir
    [J]. CLINICAL & DEVELOPMENTAL IMMUNOLOGY, 2012,
  • [2] Mechanisms of interleukin-10-mediated immune suppression
    Akdis, CA
    Blaser, K
    [J]. IMMUNOLOGY, 2001, 103 (02) : 131 - 136
  • [3] CAR T cell therapy as a promising approach in cancer immunotherapy: challenges and opportunities
    Akhoundi, Maryam
    Mohammadi, Mahsa
    Sahraei, Seyedeh Saeideh
    Sheykhhasan, Mohsen
    Fayazi, Nashmin
    [J]. CELLULAR ONCOLOGY, 2021, 44 (03) : 495 - 523
  • [4] Targeting Cancer Stem Cells by Genetically Engineered Chimeric Antigen Receptor T Cells
    Alhabbab, Rowa Y.
    [J]. FRONTIERS IN GENETICS, 2020, 11
  • [5] Bao Bin, 2013, Curr Protoc Pharmacol, VChapter 14, DOI 10.1002/0471141755.ph1425s61
  • [6] CARs: Synthetic Immunoreceptors for Cancer Therapy and Beyond
    Chang, ZeNnan L.
    Chen, Yvonne Y.
    [J]. TRENDS IN MOLECULAR MEDICINE, 2017, 23 (05) : 430 - 450
  • [7] The biology and role of CD44 in cancer progression: therapeutic implications
    Chen, Chen
    Zhao, Shujie
    Karnad, Anand
    Freeman, James W.
    [J]. JOURNAL OF HEMATOLOGY & ONCOLOGY, 2018, 11
  • [8] Adoptive T-cell therapy of prostate cancer targeting the cancer stem cell antigen EpCAM
    Deng, Zhenling
    Wu, Yanhong
    Ma, Wenbo
    Zhang, Shuren
    Zhang, Yu-Qian
    [J]. BMC IMMUNOLOGY, 2015, 16
  • [9] Design and development of therapies using chimeric antigen receptor-expressing T cells
    Dotti, Gianpietro
    Gottschalk, Stephen
    Savoldo, Barbara
    Brenner, Malcolm K.
    [J]. IMMUNOLOGICAL REVIEWS, 2014, 257 (01) : 107 - 126
  • [10] The role of CD133 in cancer: a concise review
    Glumac, Paige M.
    LeBeau, Aaron M.
    [J]. CLINICAL AND TRANSLATIONAL MEDICINE, 2018, 7
1234